In vitro evidence that rabbit distal colonic muscularis mucosae has a Clostridium difficile toxin A receptor.
In the rabbit ileum Clostridium difficile toxin A causes inflammation and mucosal damage via a specific glycoprotein receptor that contains alpha-D-galactose. In rabbit colon toxin A also causes inflammation, and this is associated with increased myoelectric activity and eicosanoid production. The present in vitro study was undertaken to determine if a toxin A receptor on one or more layers of colonic smooth muscle could mediate the motor effects of this agent. Toxin A (20-100 microg/ml) was without effect on longitudinal and circular muscle but had two different effects on the muscularis mucosae. Initial exposure to the toxin caused increased numbers of spontaneous contractions and a small, atropine-, tetrodotoxin-, and indomethacin-resistant increase in resting tone. More importantly, however, 30-min exposure to toxin A resulted in attenuated muscularis mucosae responses to acetylcholine and K+. Both the small excitatory and the larger inhibitory effects of toxin A were abolished by pretreatment with the lectin BS-1, which binds to toxin A receptors, but not by the nonreceptor-binding lectin DBA. These data strongly suggest that toxin A causes significant motor effects on the distal colonic muscularis mucosae via a receptor-mediated mechanism. These mechanical data were supported by the presence of histologically demonstrable toxin A and BS-1 binding sites on the muscularis mucosae but not on either the longitudinal or circular muscle layers, both of which were unresponsive to the toxin. By depressing muscularis mucosae function and, ultimately, mucosal movement as a result of toxin A production, C. difficile may promote its own proliferation, thus further contributing to the development of antibiotic-associated colitis.
Department of Physiology and Pharmacology, School of Medicine, University of South Dakota, Vermillion, South Dakota 57069, USA.
W H
WH
Percy
R
R
Burakoff
K
K
Rose
H P
HP
Desai
C
C
Pothoulakis
R
R
Eglow
D000109:Acetylcholine / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D001427:Bacterial Toxins; D016360:Clostridioides difficile / Q000502:physiology*; D003106:Colon / Q000378:metabolism*; D004768:Enterotoxins / Q000378:metabolism / Q000494:pharmacology*; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D007413:Intestinal Mucosa / Q000378:metabolism*; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology*; D009129:Muscle Tonus / Q000187:drug effects; D011188:Potassium / Q000494:pharmacology; D011817:Rabbits; D011971:Receptors, Immunologic / Q000378:metabolism*; D013779:Tetrodotoxin / Q000494:pharmacology
D001427:Bacterial Toxins; C080487:Clostridium difficile enterotoxin A receptor; D004768:Enterotoxins; D011971:Receptors, Immunologic; C041348:tcdA protein, Clostridium difficile; D013779:Tetrodotoxin; D000109:Acetylcholine; D011188:Potassium; D007213:Indomethacin